ArticleFrontiers in immunology2021

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.

Yuanyuan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.